| Document |
Document Title |
|
WO/2017/053733A1 |
A hydrogel delivery composition, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid stat...
|
|
WO/2017/013120A1 |
Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metaboliz...
|
|
WO/2016/204266A1 |
The purpose of the present invention is to provide a polymer film which can conform to movements of the living body or to fine ruggedness and further has excellent adhesion to biotissues. The present invention provides a polymer film whi...
|
|
WO/2016/191820A1 |
Disclosed in some forms is a process of limiting the impact of surgery on a nerve, the process comprising applying a therapeutic substance to the nerve during surgery. In some aspects, disclosed is a formulation for reducing nerve trauma...
|
|
WO/2016/184591A1 |
The present invention relates to a method of administering a composition comprising n-3 PUFAs to a patient who has received, or who is scheduled to receive, a renal transplant. Particularly, the invention provides a method to increase th...
|
|
WO/2016/175290A1 |
Provided is a composition that can be used for a preservative medium or a perfusate of internal organs. Otherwise, provided is a composition that extends the life of normal cells, and/or a composition that suppresses the life of cancer c...
|
|
WO/2016/167229A1 |
Provided is a method for producing a cross-linked product of carboxymethyl group-containing modified hyaluronic acid and/or a salt of the same, having excellent thermal stability, enzymolysis resistance and water-swelling characteristics...
|
|
WO/2016/136886A1 |
Provided is a medical/cosmetic material in which characteristics inherent in polyanionic polysaccharides, which are starting materials, are maintained, that is highly safe because there is no need to use chemical cross-linking agents dur...
|
|
WO/2016/114355A1 |
The present invention provides a composition for preventing adhesion using a combination of (a) a monovalent metal salt of low-endotoxin alginic acid, (b) carboxymethylcellulose or a pharmacologically acceptable salt thereof, and (c) cel...
|
|
WO/2016/094535A1 |
Methods and hydrogels for preventing or reducing cellular adhesion and protein adsorption to a tissue (e.g. cardiac tissue) are disclosed. The hydrogels generally include at least two component polymers, a first polymer including an amin...
|
|
WO/2016/069897A1 |
Cell-containing implants populated with endothelial cells rescue liver donor and recipient endothelium and parenchyma from ischemic injury after major hepatectomy and engraftment. The inventions disclosed herein highlight the discovery t...
|
|
WO/2016/061147A1 |
This disclosure provides a method for improving maturation of an arteriovenous fistula (AVF) in a patient in need of hemodialysis, which method entails applying a solution to the internal wall of a lumen of an AVF; and restoring or initi...
|
|
WO/2016/030278A1 |
The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme containing an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert s...
|
|
WO/2015/197098A1 |
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...
|
|
WO/2015/198245A1 |
The invention provides compositions for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and methods of using the compositions. The compositions are vitr...
|
|
WO/2015/184380A1 |
A treatment for reducing brain or other injury that can be used before, during, or after a surgical treatment or other injury to the brain to decrease or prevent subsequent damage. Injury to the brain during surgery or from other trauma ...
|
|
WO/2015/133559A1 |
Hyaluronic acid modified by sphingosine-1-phosphoric acid, and a pharmaceutical containing this hyaluronic acid as an active ingredient, the pharmaceutical making it possible to reduce liver damage due to hypoxia/reoxygenation by protect...
|
|
WO/2015/125904A1 |
[Problem] To provide an anti-human PAI-1 antibody for prevention and treatment of pulmonary fibrosis by binding to active human PAI-1 and inhibiting effects mediated by active human PAI-1. [Solution] The inventors studied anti-PAI-1 anti...
|
|
WO/2015/090232A1 |
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also pro...
|
|
WO/2015/080671A1 |
The present invention relates to the use of peptides, peptoids and/or peptidomimetics capable of self-assembling and forming a (nanofibrous) hydrogel in biofabrication. The present invention further relates to methods for preparing hydro...
|
|
WO/2015/060430A1 |
The purpose of the present invention is to provide a method for screening substances that participate in metabolic conversion and a kit for screening substances that participate in metabolic conversion. Said problem can be solved with mu...
|
|
WO/2015/006831A9 |
The invention relates to compositions and methods for reducing at least one of inflammation, coagulation, adhesions and scar formation in an injured subject or inducing a hypotensive state or a iow pain or analgesic state in an injured s...
|
|
WO/2015/029892A1 |
A method for manufacturing a water-insoluble molded article having a step for treating a starting material molded article composed of a water-soluble salt of a polyanionic polysaccharide using a treatment liquid containing an acid anhydr...
|
|
WO/2015/012730A1 |
A method is proposed for making biodegradable membranes intended for preventing development of an adhesive disease following open heart surgery. The production of the biodegradable membranes is carried out on the basis of a polymer co...
|
|
WO/2015/006829A1 |
The invention relates to a composition or method for treating at least one of infection, sepsis and injury or inducing a hypotensive state or a low pain or analgesic state in a subject susceptible to or suffering from at least one of inf...
|
|
WO/2014/206427A1 |
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...
|
|
WO/2014/185309A1 |
Provided is a substance for preventing adhesion characterized by containing: (1) an A-B-A type or B-A-B type triblock copolymer in which the A segment contains a poly (ε-caprolactone- co- glycolic acid) and the B segment contains a poly...
|
|
WO/2014/178256A1 |
The present invention relates to an adhesion preventing agent which comprises an amphiphilic compound represented by general formula (I). (In the formula, X and Y each represents a hydrogen atom or together represent an oxygen atom, n re...
|
|
WO/2014/170563A1 |
The invention relates to a gaseous composition containing xenon as active ingredient for use in preventing or limiting tumour cell migration and/or limiting or preventing metastasis formation in an individual suffering from cancer. The p...
|
|
WO/2014/142933A1 |
The present invention is related to methods and compositions useful in the detection and treatment of neuroimmunological exacerbation of traumatic, autoimmune and other disease processes. The methods described herein comprise identifying...
|
|
WO/2014/129382A1 |
The present invention provides a means for improving the solubility of a polysaccharide in water. Provided is a polysaccharide powder having a particle size distribution in which the particle size of 30 vol% or more of the total volume i...
|
|
WO/2014/113836A1 |
The present invention provides a method of treating a seaweed extract comprising a target molecule and a pyrogenic agent, the method comprising the step(s) of: inactivating the pyrogenic agent and/or removing the pyrogenic agent, wherein...
|
|
WO/2014/081025A1 |
This invention relates to an I-form crystal of the free form of 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyetho
xy)-5-(3-oxo-[1,2]-oxazinan-2-ylmethyl)benzamide, the crystal, in analysis by X-ray powder diffraction with CuKÎ...
|
|
WO/2014/058343A1 |
The invention relates to the art of medicine, and more particularly to injectable bioresorbable compositions of biocomposite materials for treating diseases of and damage to the human skeletal system as a material that is capable of full...
|
|
WO/2014/056723A1 |
The subject matter of the present invention is a ready-to-use, resorbable, injectable, sterile aqueous formulation used for therapeutic purposes, in the form of a particulate cohesive viscoelastic gel comprising i) crosslinked hyaluronic...
|
|
WO/2013/168807A1 |
Disclosed are: an additive for a graft cell suspension, the additive comprising a dispirotripiperazine derivative represented by formula (I) or (II), or a salt thereof; a therapeutic composition comprising cells and the dispirotripiperaz...
|
|
WO/2013/138916A1 |
Chitosan nanoparticles are provided for use in the in vivo treatment of connective tissues in root canal therapies. The nanoparticles are optionally linked with one or more photoactivatable compounds for providing antibactenal/antibiofil...
|
|
WO/2013/142374A1 |
Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when...
|
|
WO/2013/133413A1 |
A mucosa-elevating agent containing 0.1-1.0% peptides, wherein the peptides are an amphipathic peptide to which a hydrophilic amino acid and a hydrophobic amino acid are bonded in alternation and which has 8-200 amino acid residues, and ...
|
|
WO/2013/109811A1 |
The invention provides a composition for use in tissue augmentation of a human. More specifically, the composition comprises collagen extracted from human placenta and a bulking agent. Furthermore, the invention discloses methods of augm...
|
|
WO/2013/032201A2 |
The present invention relates to a material for preventing adhesion including hyaluronic acid, carboxymethyl cellulose, and alginate, and to a method for preventing adhesion at a local tracheal surface using the material for preventing a...
|
|
WO/2013/018759A1 |
Provided is an anti-adhesion medical material in which a polyhydric alcohol or a polyhydric alcohol aqueous solution containing a polyhydric alcohol is retained in a bioabsorbable base material that contains a bioabsorbable material and ...
|
|
WO/2013/018864A1 |
The aim of the present invention lies in providing an anti-adhesion membrane which can be easily rolled into a tube-shape without being damaged, and inserted into the body through a trocar, and which also has suitable resilience and is v...
|
|
WO/2012/156938A1 |
The invention relates to the field of pharmacy, clinical and experimental medicine and veterinary medicine, and in particular to novel inhibitory compounds of a p38 MAP kinase with a structure of the type (I)-(VII) which can be used for ...
|
|
WO/2012/149358A1 |
The invention provides polymer compositions for cell and drug delivery.
|
|
WO/2012/138212A1 |
The present invention pertains to a liquid nutritional composition comprising fat and proteinaceous matter, wherein said fat contributes for at least 41 En% and said proteinaceous matter contributes for at least 23 En% to the total energ...
|
|
WO/2012/133295A1 |
Provided is a bioabsorbable antiadhesive material the arrangement state of which can be checked without incising a patient. This bioabsorbable antiadhesive material is made from a bioabsorbable material which contains a contrast medium. ...
|
|
WO/2012/108831A1 |
Use of a metabotropic glutamate receptor group I antagonist, or a pharmaceutically acceptable salt, prodrug or an optical isomer thereof, for the manufacture of a medicament for the treatment or the prevention of abnormal union of tissue...
|
|
WO/2012/100050A1 |
The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological...
|
|
WO/2012/072374A1 |
The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combina...
|
